Fundamental Analysis of Titan Pharmaceuticals Inc - Growth / Value Index
TTNP - Valuation Highlights
Valuation Analysis
Valuation Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ |
|---|---|---|---|---|
| Price to Earning | -0.821 | -0.773 | -85.34 % | |
| Price to Book | 1.20 | 0.718 | -77.03 % | 0.746 |
| Price to Sales | 28.65 | 91.69 | 1099.21 % | |
| Enterprise Value to EBITDA Multiple | 0.119 | 0.321 | 322.98 % |
TTNP - Profitability Highlights
Profitability Analysis
Annual Net Profit in last 3 years is trending up
EBITDA is continuously increasing for last 3 Years
Tsr Profitability Index - Very Poor Score of 5.00
Negative Net profit for last two years
Company Net profit is Negative for last 5 Quarters
In the last three years, the company has given poor Returns on Equity
In the last three years, the company has given poor Returns on Assets
Profitability Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ |
|---|---|---|---|---|
| Return On Equity | -146.08 | -92.82 | 87.60 % | -29.66 |
| Return On Asset | -100.58 | -76.24 | 69.69 % | -24.36 |
| Net Profit Margin | -3490.48 | -11855.77 | -547.04 % | -2432.10 |
| Operating Profit Margin | -4470.83 | -15301.92 | -732.75 % | -2383.95 |
| EBITDA Margin | -4490.48 | -11559.62 | -541.37 % | -2380.25 |
Highlights
| Market Cap | 5796.24 K |
| Enterprise Value | -898756.44 |
| Price/Book TTM | 1.20 |
| Outstanding Share | 914234 |
| Float/ Outstanding Share | 76.56% |
| Dividend Yield | 2.65 % |
Share Holding
Guru Numbers
| Price/Graham No | 0 |
| Peter Lynch Ratio | 0 |
| Piotroski F Score | 3.00 |
| Altman Z Score | -66.95 |
| Sloan Ratio | 0.0322 |
| Peter Lynch Fair Value | 0 |
TTNP - Growth Highlights
Growth Analysis
YoY Net Margin Jump by 547.04%
Tsr Growth Index - Poor Score of 34.14
Quarterly sales in last 5 Quarter is trending down
Annual sales in last 3 years is trending down
Companies' sales dropped by 90.66 % from last year
Growth Key Fields
| Field | TTM | YoY Growth | QoQ Growth |
|---|---|---|---|
| Revenue | 168000 | 90.66 % | % |
| Gross Profit | 84000.00 | 62.98 % | % |
| EBITDA | -7544.00 K | 40.12 % | 1.98 % |
| Net Profit | -5864.00 K | 39.59 % | 0 % |
| EPS | -7.72 | 46.04 % | NA |
TTNP - Stability Highlights
Stability Analysis
Debt to equity ratio has decreased and is lowest in last five years
Cash ratio of 4.68
Company financial liquidity has improved
Altman Z Score of -66.87 suggest high risk
Company is unable to generate enough free cash to support the business.
Interest Coverage of 0
Stability Key Ratios
| Ratio | Latest FY | Yoy Change | MRQ |
|---|---|---|---|
| Debt to Equity Ratio | 0.0098 | -89.07 % | 0.085 |
| Cash Ratio | 4.68 | 319.21 % | |
| Quick Ratio | 0 | 0 % | 5.55 |
| Shareholders Equity | 82.14 | 144.56 % | |
| Debt to EBITDA | -0.0108 | 11.02 % |
Historical Valuation Ratios of Titan Pharmaceuticals Inc
Historical Valuation Ratios
Loading ...
Historical Profitability Ratios of Titan Pharmaceuticals Inc
Historical Profitability Ratios
Loading ...
Historical Efficiency Ratios of Titan Pharmaceuticals Inc
Historical Efficiency Ratios
Loading ...
Historical Solvency Ratios of Titan Pharmaceuticals Inc
Historical Solvency Ratios
Loading ...
Note : All Data Generated at the End of Trading Hours (EOD Data)